ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NPTX Neuropathix Inc (CE)

0.0003
0.00 (0.00%)
Mar 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0.00
Bid Price
Ask Price
News -
Day High

Low
0.0002

52 Week Range

High
0.0004

Day Low
Company Name Stock Ticker Symbol Market Type
Neuropathix Inc (CE) NPTX OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.0003 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.0003
Trades Volume Avg Volume 52 Week Range
0 0.00 - 0.0002 - 0.0004
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.0003 USD

Neuropathix Inc (CE) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 29.31k 97.70M 21.52M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Neuropathix (CE) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NPTX Message Board. Create One! See More Posts on NPTX Message Board See More Message Board Posts

Historical NPTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.00030.00030.00030.000369,6270.000.00%
1 Year0.00040.00040.00020.000240446,020-0.0001-25.00%
3 Years0.200.200.00020.045107365,089-0.1997-99.85%
5 Years0.330.8050.00020.099123773,849-0.3297-99.91%

Neuropathix (CE) Description

Neuropathix, Inc., formerly Kannalife, Inc. ("Neuropathix"), is a socially responsible pain management life sciences company. For the past ten years, Neuropathix has discovered, developed and patented a global intellectual property estate of novel new therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Neuropathix was the only company to hold an exclusive license with National Institutes of Health - Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent"). This early and extensive pre-clinical research on cannabidiol (CBD) led Neuropathix to develop its own patented molecules lead by KLS-13019 called by Sports Illustrated as a "super-CBD" and currently covered under global patents awarded including U.S. Patent #9611213, "Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy". Neuropathix continues to conduct its research and development efforts at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA. The company's lead candidate KLS-13019 is a viable non-opioid solution for treating Chemotherapy Induced Peripheral Neuropathy ("CIPN"). The Company's wholly owned subsidiary Dermique Incorporated now holds all the IP for LEA, its patented compound that is simply better than CBD for treating topical skin disorders.

Your Recent History

Delayed Upgrade Clock